Pharmanest meets all efficacy and safety end points in Phase II study of SHACT

STOCKHOLM – August 1, 2013. Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show that SHACT is effective in reducing pain in connection with intrauterine device insertion. Karolinska Development owns 63% of Pharmanest*.Every year, millions of women around the world experience pain and discomfort during IUD insertion (intrauterine contraception). There are few treatment options with proven efficacy and safety available to these women. SHACT is a product based on an innovative formulation of lidocaine, a well-